NASDAQ:BMRN - BioMarin Pharmaceutical Stock Price, Forecast & News

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings results on Wednesday, October, 23rd. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.06 by $0.25. The biotechnology company earned $461.10 million during the quarter, compared to the consensus estimate of $455.78 million. BioMarin Pharmaceutical had a negative return on equity of 1.35% and a negative net margin of 2.65%. BioMarin Pharmaceutical's revenue for the quarter was up 17.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.07) earnings per share. View BioMarin Pharmaceutical's Earnings History.

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for BioMarin Pharmaceutical.

15 Wall Street analysts have issued twelve-month target prices for BioMarin Pharmaceutical's stock. Their forecasts range from $77.00 to $158.00. On average, they anticipate BioMarin Pharmaceutical's stock price to reach $112.38 in the next twelve months. This suggests a possible upside of 31.2% from the stock's current price. View Analyst Price Targets for BioMarin Pharmaceutical.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioMarin Pharmaceutical.

News headlines about BMRN stock have trended very positive on Friday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioMarin Pharmaceutical earned a daily sentiment score of 3.9 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for BioMarin Pharmaceutical.

BioMarin Pharmaceutical saw a increase in short interest in December. As of December 31st, there was short interest totalling 8,700,000 shares, an increase of 14.3% from the December 15th total of 7,610,000 shares. Based on an average trading volume of 1,450,000 shares, the days-to-cover ratio is currently 6.0 days. Approximately 4.9% of the shares of the stock are sold short. View BioMarin Pharmaceutical's Current Options Chain.

Some companies that are related to BioMarin Pharmaceutical include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Celgene (CELG), Array Biopharma (ARRY) and Freeport-McMoRan (FCX).

BioMarin Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Manning & Napier Group LLC (0.61%), Scout Investments Inc. (0.22%), Rhenman & Partners Asset Management AB (0.12%), DNB Asset Management AS (0.05%), United Services Automobile Association (0.03%) and Gradient Investments LLC (0.02%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.

BMRN stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, CMH Wealth Management LLC, Ironsides Asset Advisors LLC, Gateway Investment Advisers LLC, United Services Automobile Association, Wealthstreet Investment Advisors LLC, Janney Montgomery Scott LLC and IFM Investors Pty Ltd. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical.

BMRN stock was acquired by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Scout Investments Inc., DNB Asset Management AS, Pegasus Asset Management Inc., Gradient Investments LLC, Wedbush Securities Inc., Nisa Investment Advisors LLC and D.B. Root & Company LLC. View Insider Buying and Selling for BioMarin Pharmaceutical.

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BMRN stock can currently be purchased for approximately $85.63.

BioMarin Pharmaceutical has a market capitalization of $15.38 billion and generates $1.49 billion in revenue each year. The biotechnology company earns $-77,210,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. BioMarin Pharmaceutical employs 2,849 workers across the globe.View Additional Information About BioMarin Pharmaceutical.

The official website for BioMarin Pharmaceutical is http://www.bmrn.com/.

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]